Avutometinib potassium is under clinical development by Verastem and currently in Phase III for Fallopian Tube Cancer. According to GlobalData, Phase III drugs for Fallopian Tube Cancer have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Avutometinib potassium’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Likelihood of Approval and Phase Transition Success Rate Model - Avutometinib Potassium in Fallopian Tube Cancer

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Avutometinib potassium overview

Avutometinib potassium (RG-7304, RO5126766) is under development for the treatment of solid tumors including low-grade serous ovarian cancer (LGSOC) , peritoneal cancer, gastroesophageal junction carcinoma, fallopian tube cancer, metastatic uveal melanoma, brain metastases from cutaneous melanoma, metastatic pancreatic cancer, pancreatic ductal adenocarcinoma, metastatic adenocarcinoma of the pancreas, non-small cell lung cancer, multiple myeloma, glioblastoma, recurrent glioblastoma, endometrial cancer, prostate cancer, cervical cancer, HER2 negative breast cancer, anaplastic thyroid cancer, papillary thyroid carcinoma, follicular thyroid carcinoma and colorectal cancer. It is administered orally as a capsule. It is a new molecular entity (NME) with a structure based on a coumarin skeleton. The drug candidate acts by targeting B-Raf kinase, C-Raf kinase, mitogen activated protein kinase kinase 1 (MEK-1 or MAP2K1). It was also under development for melanoma, pancreatic cancer and solid tumors in Japan.

Verastem overview

Verastem is a development-stage biopharmaceutical company that provides the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Verastem pipeline programs include Avutometinib and Defactinib. The company pipeline is focused on novel small-molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and focal adhesion kinase (FAK) inhibition. The company operates in Germany and the US. Verastem is headquartered in Needham, Massachusetts, the US.

For a complete picture of Avutometinib potassium’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 16 July 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.